Company · founded 2009
Privo Technologies (United States)
Cambridge, United States · privotechnologies.com
- Citations, last 5 years
- 79
- Works, last 5 years
- 4
- h-index
- 14
- Scientists listed
- 1
- Grants since 2016
- 17
Grants received
2024–2027 · research · R44
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2024–2027 · research · R44
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2022 · research · R44
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2022–2024 · contract · N44
TOPIC TITLE: CANCER TREATMENT TECHNOLOGIES FOR LOW-RESOURCE SETTINGSPROJECT TITLE: PRV311: A STANDALONE, SAFE, EFFECTIVE, AND AFFORDABLE TREATMENT FO
Manijeh Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2022–2025 · research · R44
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2022–2026 · research · R44
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2019–2023 · research · R01
Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017
Manijeh N Goldberg · Privo Technologies (United States) · funded by U.S. Food and Drug Administration
2019–2022 · research · R01
Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017
Manijeh N Goldberg · Privo Technologies (United States) · funded by U.S. Food and Drug Administration
2019–2023 · research · R01
Highly focused loco-regional chemotherapy for oral cancer - IND 132234 - October 01 2017
Manijeh N Goldberg · Privo Technologies (United States) · funded by U.S. Food and Drug Administration
2019–2020 · research · R44
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2015–2020 · research · R44
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2015–2021 · research · R44
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2014–2024 · research · R44
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2014–2024 · research · R44
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
2014–2025 · research · R44
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy
Manijeh N Goldberg · Privo Technologies (United States) · funded by National Institutes of Health
